Come up with a name for your new list and we'll add to it:
Syndax Pharmaceuticals raised a round of funding on April 06, 2015. Investors include
Merck & Co..
Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immuno…